Is Tyme Technologies Inc (TYME) Stock About to Get Hot Thursday?

Thursday, August 04, 2022 12:03 PM | InvestorsObserver Analysts

Mentioned in this article

Is Tyme Technologies Inc (TYME) Stock About to Get Hot Thursday?

Overall market sentiment has been high on Tyme Technologies Inc (TYME) stock lately. TYME receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Tyme Technologies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TYME!

See Full TYME Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With TYME Stock Today?

Tyme Technologies Inc (TYME) stock is trading at $0.33 as of 12:02 PM on Thursday, Aug 4, a rise of $0.03, or 9.67% from the previous closing price of $0.30. The stock has traded between $0.32 and $0.35 so far today. Volume today is low. So far 1,030,764 shares have traded compared to average volume of 2,066,627 shares. To see InvestorsObserver's Sentiment Score for Tyme Technologies Inc click here.

More About Tyme Technologies Inc

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer. Click Here to get the full Stock Report for Tyme Technologies Inc stock.